2011-06-07
The Public Health Impact of Antiviral Therapy for Chronic Hepatitis B
Publication
Publication
Het publieke gezondheidseffect van antivirale therapie voor chronische hepatitis B
Abstract
Of the approximately 2 billion people who have been infected worldwide with the hepatitis B virus (HBV), more than 350 million are chronic carriers. HBV infection accounts for 600,000-1,200,000 deaths each year. Chronic viral hepatitis B is a major global public health problem, an important cause of morbidity and mortality from sequelae, which include chronic hepatitis, cirrhosis, and primary liver cancer. Because the course of the disease can go without clinical symptoms for a long time it is a ‘silent’ disease, and the contribution of chronic hepatitis B to global morbidity and mortality is generally underestimated.
| Additional Metadata | |
|---|---|
| , , , , | |
| J.H. Richardus (Jan Hendrik) | |
| Part of the research in this thesis was financially supported by the VIRGIL EU Grant (LSHM-CT-2004-503359), LiverDoc, and EASL Sheila Sherlock fellowship. Financial support for the publication of this thesis was given by Erasmus University Rotterdam, the Department of Public Health, Erasmus MC University Medical Center, and LiverDoc. | |
| hdl.handle.net/1765/51635 | |
| Organisation | Erasmus MC: University Medical Center Rotterdam |
|
Toy, M. (2011, June 7). The Public Health Impact of Antiviral Therapy for Chronic Hepatitis B. Part of the research in this thesis was financially supported by the VIRGIL EU Grant (LSHM-CT-2004-503359), LiverDoc, and EASL Sheila Sherlock fellowship. Financial support for the publication of this thesis was given by Erasmus University Rotterdam, the Department of Public Health, Erasmus MC University Medical Center, and LiverDoc. Retrieved from http://hdl.handle.net/1765/51635 |
|
